These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 32642198)

  • 1. Mechanisms of resistance to osimertinib.
    Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
    J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
    Santarpia M; Liguori A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; D'Aveni A; Marabello G; Altavilla G; Rosell R
    Lung Cancer (Auckl); 2017; 8():109-125. PubMed ID: 28860885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of T790M Mutation Status on Later-Line Osimertinib Treatment in Non-Small Cell Lung Cancer Patients.
    Tang YJ; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
    Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
    J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Sun JM; Park K
    Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors.
    Wu L; Ke L; Zhang Z; Yu J; Meng X
    Front Oncol; 2020; 10():602762. PubMed ID: 33392095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
    Le T; Gerber DE
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
    Saad N; Poudel A; Basnet A; Gajra A
    Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use.
    Scott LJ
    Drugs Ther Perspect; 2018; 34(8):351-357. PubMed ID: 30631243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.
    Choo JR; Tan CS; Soo RA
    Target Oncol; 2018 Apr; 13(2):141-156. PubMed ID: 29423594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
    Ang YLE; Zhao X; Reungwetwattana T; Cho BC; Liao BC; Yeung R; Loong HH; Kim DW; Yang JC; Lim SM; Ahn MJ; Lee SH; Suwatanapongched T; Kongchauy K; Ou Q; Yu R; Tai BC; Goh BC; Mok TSK; Soo RA
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired Concurrent EGFR T790M and Driver Gene Resistance From EGFR-TKIs Hampered Osimertinib Efficacy in Advanced Lung Adenocarcinoma: Case Reports.
    Zeng Y; Feng Y; Fu G; Jiang J; Liu X; Pan Y; Hu C; Liu X; Wu F
    Front Pharmacol; 2022; 13():838247. PubMed ID: 35462930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Making progress in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer by surpassing resistance: third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs).
    Mountzios G
    Ann Transl Med; 2018 Apr; 6(8):140. PubMed ID: 29862229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors.
    Doval DC; Desai CJ; Sahoo TP
    Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in
    Haratake N; Misumi T; Yamanaka T; Seto T
    JTO Clin Res Rep; 2020 Nov; 1(4):100085. PubMed ID: 34589964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT).
    Addeo A; Hochmair M; Janzic U; Dudnik E; Charpidou A; Płużański A; Ciuleanu T; Donev IS; Elbaz J; Aarøe J; Ott R; Peled N
    Ther Adv Med Oncol; 2021; 13():17588359211059874. PubMed ID: 35173817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced
    Zhang D; Liu X; Shen F; Zhao D; Shi Y; Zhang H; Liu J; Gao X; Chen M; Zhao J; Zhong W; Gao J; He M; Liu Y; Yang X; Qin J; Tang Y; Mu X; Gu Y; Zhang S; Chen X; Pang L; Meng Q; Guo Y; Zhang Y; Li W; Xing P; Cheng Y; Xin T; Li Q; Li Y; Chen J; Gao F; Jin B; Rossi A; Adachi H; Guerrera F; Husain H; Xu Y; Wang M
    Transl Lung Cancer Res; 2023 Nov; 12(11):2229-2244. PubMed ID: 38090527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.